Patents by Inventor Robin EDWARDS
Robin EDWARDS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12259848Abstract: A distributed storage system may synchronously apply an Information Lifecycle Management (ILM) policy to objects at ingest. In one embodiment of synchronous ILM, three options are available for a user: balanced, strict, and dual commit. Dual commit refers to the behavior where one will always create two replicated copies in the same site and then apply ILM asynchronously. Strict refers to the behavior where the storage system attempts to apply the ILM policy synchronously on ingest, and if the storage system cannot the ingest of the object will fail. This ensures that the storage system can guarantee that ILM has been applied to recently ingested objects. Balanced refers to the behavior where the storage system attempts to apply ILM synchronously, but if the storage system cannot the storage system may fall-back to dual-commit.Type: GrantFiled: December 12, 2022Date of Patent: March 25, 2025Assignee: NETAPP, INC.Inventors: Robin Mahony, Oliver Seiler, Blake Edwards, Vladimir Avram, Gregory Kent, Chong Zhao
-
Patent number: 12246131Abstract: A patient interface includes a frame assembly including connectors operatively attachable to headgear, a cushion assembly provided to the frame assembly and including a seal-forming structure structured to form a seal with the patient's nose and/or mouth, and an air delivery connector provided to the frame assembly and operatively connected to an air delivery tube for supplying the air at positive pressure along an air flow path. The cushion assembly is structured to releasably connect to the frame assembly independently of the air delivery connector. The air delivery connector is structured to releasably connect to the frame assembly independently of the cushion assembly.Type: GrantFiled: November 23, 2021Date of Patent: March 11, 2025Assignee: RESMED PTY LTDInventors: Amal Shirley Amarasinghe, Ravikumar Baluchagi, Adam Francis Barlow, Andrew James Bate, Emily Elizabeth Blanch, David James Braund, Christopher Samuel Cullen, Errol Savio Alex D'Souza, Bruce Richard Davies, Craig David Edwards, Christopher Andrew Wakeley Gill, Lachlan Richard Goldspink, Thomas Kirby, Kishore Markapuram Chengalvarayan, Holly Elizabeth Miller, Lemmy Nga, Chia Ik Tan, Matthew Robin Wells
-
Patent number: 12227576Abstract: This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, the tumor is derived from a non-small cell lung cancer (NSCLC). In some embodiments, the tumor expresses Programmed Death Ligand 1. In some embodiments, the subject carries a wild-type STK11 gene.Type: GrantFiled: January 30, 2023Date of Patent: February 18, 2025Assignee: Bristol-Myers Squibb CompanyInventors: Robin Edwards, William J. Geese, Danielle M. Greenawalt
-
Publication number: 20250043006Abstract: The invention provides a method of treating a tumor in a human patient comprising (i) identifying a patient as having a LAG-3 positive tumor and (ii) administering to the patient a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. In some embodiments, the method further comprises identifying the patient as having a LAG-3 positive PD-L1 positive tumor. In some embodiments, the LAG-3 inhibitor is an anti-LAG-3 antibody and the PD-1 pathway inhibitor is an anti-PD-1 antibody. The methods of the invention can improve response rates to treatment with a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, or a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor.Type: ApplicationFiled: June 17, 2024Publication date: February 6, 2025Applicant: Bristol-Myers Squibb CompanyInventors: James NOVOTNY, Nils LONBERG, Cyrus HEDVAT, Raphael CLYNES, Darren LOCKE, John P. COGSWELL, Jeffrey JACKSON, Christopher HARBISON, Robin EDWARDS
-
Patent number: 12049503Abstract: The invention provides a method of treating a tumor in a human patient comprising (i) identifying a patient as having a LAG-3 positive tumor and (ii) administering to the patient a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. In some embodiments, the method further comprises identifying the patient as having a LAG-3 positive PD-L1 positive tumor. In some embodiments, the LAG-3 inhibitor is an anti-LAG-3 antibody and the PD-1 pathway inhibitor is an anti-PD-1 antibody. The methods of the invention can improve response rates to treatment with a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, or a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor.Type: GrantFiled: August 18, 2023Date of Patent: July 30, 2024Assignee: Bristol-Myers Squibb CompanyInventors: James Novotny, Nils Lonberg, Cyrus Hedvat, Raphael Clynes, Darren Locke, John P. Cogswell, Jeffrey Jackson, Christopher Harbison, Robin Edwards
-
Publication number: 20240127451Abstract: Described herein are methods and computer systems for classification of CD8 T-cell topology using a patient response-based linear cutoff model. A plurality of histology images of tissue samples in a plurality of patients are received by a computer system. An image analysis of the plurality of histology images is performed to obtain a CD8+ T-cell abundance in the tumor parenchyma and stroma in each of the plurality of histology images. Real inflammation scores and tumor infiltration scores are determined based on a polar coordinate transformation of the CD8+ T-cell abundance in the tumor parenchyma and stroma. Based on the real inflammation scores and tumor infiltration scores, a feature space is generated, and linear boundaries or linear cutoffs between a plurality of classifications in the feature space are identified based on the real inflammation scores, the tumor infiltration scores, and patient response data.Type: ApplicationFiled: February 25, 2022Publication date: April 18, 2024Applicant: Bristol-Myers Squibb CompanyInventors: George C. Lee, Robin Edwards, Scott Ely, Daniel N. Cohen, John B. Wojcik, Vipul A. Baxi, Dimple Pandya, Jimena Trillo-Tinoco, Benjamin J. Chen, Andrew Fisher, Falon Gray
-
Publication number: 20240092911Abstract: The invention provides a method of treating a tumor in a human patient comprising (i) identifying a patient as having a LAG-3 positive tumor and (ii) administering to the patient a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. In some embodiments, the method further comprises identifying the patient as having a LAG-3 positive PD-L1 positive tumor. In some embodiments, the LAG-3 inhibitor is an anti-LAG-3 antibody and the PD-1 pathway inhibitor is an anti-PD-1 antibody. The methods of the invention can improve response rates to treatment with a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, or a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor.Type: ApplicationFiled: August 18, 2023Publication date: March 21, 2024Applicant: Bristol-Myers Squibb CompanyInventors: James NOVOTNY, Nils LONBERG, Cyrus HEDVAT, Raphael CLYNES, Darren LOCKE, John P. COGSWELL, Jeffrey JACKSON, Christopher HARBISON, Robin EDWARDS
-
Patent number: 11807686Abstract: The invention provides a method of treating a tumor in a human patient comprising (i) identifying a patient as having a LAG-3 positive tumor and (ii) administering to the patient a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. In some embodiments, the method further comprises identifying the patient as having a LAG-3 positive PD-L1 positive tumor. In some embodiments, the LAG-3 inhibitor is an anti-LAG-3 antibody and the PD-1 pathway inhibitor is an anti-PD-1 antibody. The methods of the invention can improve response rates to treatment with a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, or a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor.Type: GrantFiled: May 30, 2018Date of Patent: November 7, 2023Assignee: Bristol-Myers Squibb CompanyInventors: James Novotny, Jr., Nils Lonberg, Cyrus Hedvat, Raphael Clynes, Darren Locke, John P. Cogswell, Jeffrey Jackson, Christopher Harbison, Robin Edwards
-
Publication number: 20230306762Abstract: Described herein are methods and computer systems for classification of CD8 T-cell topology using artificial intelligence and machine learning. A plurality of histology images of tissue samples in a plurality of patients are received by a computer system. An image analysis of the plurality of histology images is performed to obtain a CD8+ T-cell abundance in the tumor parenchyma and stroma in each of the plurality of histology images. A machine learning algorithm is then trained using results of the image analysis and the CD8+ T-cell abundance in the tumor parenchyma and stroma. Based on the training, a machine learning feature space comprising a plurality of classifications is generated, and boundaries between the plurality of classifications in the machine learning feature space are identified.Type: ApplicationFiled: August 31, 2021Publication date: September 28, 2023Applicant: Bristol-Myers Squibb CompanyInventors: George C. LEE, Robin EDWARDS, Scott ELY, Daniel N. COHEN, John B. WOJCIK, Vipul A. BAXI, Dimple PANDYA, Jimena TRILLO-TINOCO, Benjamin J. CHEN, Andrew FISHER, Falon GRAY
-
Publication number: 20230303700Abstract: The present disclosure provides methods of identifying a subject suitable for an anti-PD-?PD-L1 antagonist therapy comprising measuring assay CD8 localization and PD-L1 expression in a tumor sample obtained from the subject. In some aspects, method further comprises administering (i) an anti-PD-?PD-L1 antagonist therapy or (ii) an anti-PD-?PD-L1 antagonist and anti-CT-LA-4 antagonist combination therapy to a subject identified as having a tumor exhibiting an excluded CD8 localization phenotype, wherein the tumor is PD-L1 negative.Type: ApplicationFiled: August 31, 2021Publication date: September 28, 2023Applicant: Bristol-Myers Squibb CompanyInventors: George C. LEE, Robin EDWARDS, Scott ELY, Daniel N. COHEN, John B. WOJCIK, Vipul A. BAXI, Dimple PANDYA, Jimena TRILLO-TINOCO, Benjamin J. CHEN, Andrew FISHER, Falon GRAY
-
Publication number: 20230279114Abstract: This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, the tumor is derived from a non-small cell lung cancer (NSCLC). In some embodiments, the tumor expresses Programmed Death Ligand 1. In some embodiments, the subject carries a wild-type STK11 gene.Type: ApplicationFiled: January 30, 2023Publication date: September 7, 2023Applicant: Bristol-Myers Squibb CompanyInventors: Robin EDWARDS, William J. GEESE, Danielle M. GREENAWALT
-
Patent number: 11566073Abstract: This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, the tumor is derived from a non-small cell lung cancer (NSCLC). In some embodiments, the tumor expresses Programmed Death Ligand 1. In some embodiments, the subject carries a wild-type STK11 gene.Type: GrantFiled: June 1, 2018Date of Patent: January 31, 2023Assignee: Bristol-Myers Squibb CompanyInventors: Robin Edwards, William J. Geese, Danielle M. Greenawalt
-
Publication number: 20220348653Abstract: The disclosure provides LAG-3 antagonists and methods comprising the same for treating a cancer in a subject based on a LAG-3 density score and/or a LAG-3 proportion score in a tumor sample from the subject. The disclosure also provides methods of identifying a subject responsive to a LAG-3 antagonist therapy.Type: ApplicationFiled: September 22, 2020Publication date: November 3, 2022Applicant: Bristol-Myers Squibb CompanyInventors: Cyrus HEDVAT, Robin EDWARDS, George C. LEE, Vipual Atulkumar BAXI
-
Publication number: 20220315657Abstract: This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, the tumor is derived from a non-small cell lung cancer (NSCLC). In some embodiments, the tumor expresses Programmed Death Ligand 1 (PD-L1), Serine/Threonine Kinase 11 (STK11), or both PD-L1 and STK11.Type: ApplicationFiled: March 21, 2022Publication date: October 6, 2022Applicant: Bristol-Myers Squibb CompanyInventors: Robin EDWARDS, Han CHANG, Michele CLEARY, Peter M. SZABO, Joseph Daniel SZUSTAKOWSKI, Patrik VITAZKA
-
Publication number: 20210261666Abstract: The invention provides a method of treating a tumor in a human patient comprising (i) identifying a patient as having a LAG-3 positive tumor and (ii) administering to the patient a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. In some embodiments, the method further comprises identifying the patient as having a LAG-3 positive PD-Ll positive tumor. In some embodiments, the LAG-3 inhibitor is an anti-LAG-3 antibody and the PD-1 pathway inhibitor is an anti-PD-1 antibody. The methods of the invention can improve response rates to treatment with a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, or a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor.Type: ApplicationFiled: May 30, 2018Publication date: August 26, 2021Applicant: Bristol-Myers Squibb CompanyInventors: James NOVOTNY, JR., Nils LONBERG, Cyrus HEDVAT, Raphael CLYNES, Darren LOCKE, John P. COGSWELL, Jeffrey JACKSON, Christopher HARBISON, Robin EDWARDS
-
Patent number: 10989178Abstract: A method of electricity production using water thermal energy includes compressing an enclosed working fluid at a first vertical position relative to a surface of a body of water to cause the fluid to move to a second vertical position relative to the surface and subsequently move to the first position in a closed loop, an external environment at the second position having a greater temperature than an external environment at the first position such that the fluid transitions between a liquid phase at the first position and a vapor phase at the second position, the compressing using power from a battery, and expanding the fluid at the second position to generate electricity to charge the battery. The first and second positions may be two depths of the body of water or a height of an atmosphere above the body of water and a depth of the body of water.Type: GrantFiled: September 6, 2019Date of Patent: April 27, 2021Assignee: Seatrec, Inc.Inventors: Jack A. Jones, Yi Chao, David M. Fratantoni, Michael Martin Zedelmair, Robin Edward Willis, Robert Scott Leland
-
Publication number: 20200325226Abstract: This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, the tumor is derived from a non-small cell lung cancer (NSCLC). In some embodiments, the tumor expresses Programmed Death Ligand 1 (PD-L1), Serine/Threonine Kinase 11 (STK11), or both PD-L1 and STK11.Type: ApplicationFiled: June 2, 2017Publication date: October 15, 2020Applicant: Bristol-Myers Squibb CompanyInventors: Robin EDWARDS, Han CHANG, Michele CLEARY, Peter M. SZABO, Joseph D. SZUSTAKOWSKI, Patrik VITAZKA
-
Publication number: 20200109204Abstract: This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, the tumor is derived from a non-small cell lung cancer (NSCLC). In some embodiments, the tumor expresses Programmed Death Ligand 1. In some embodiments, the subject carries a wild-type STK11 gene.Type: ApplicationFiled: June 1, 2018Publication date: April 9, 2020Applicant: Bristol-Myers Squibb CompanyInventors: Robin EDWARDS, William J. GEESE, Danielle M. GREENAWALT
-
Publication number: 20200003188Abstract: A method of electricity production using water thermal energy includes compressing an enclosed working fluid at a first vertical position relative to a surface of a body of water to cause the fluid to move to a second vertical position relative to the surface and subsequently move to the first position in a closed loop, an external environment at the second position having a greater temperature than an external environment at the first position such that the fluid transitions between a liquid phase at the first position and a vapor phase at the second position, the compressing using power from a battery, and expanding the fluid at the second position to generate electricity to charge the battery. The first and second positions may be two depths of the body of water or a height of an atmosphere above the body of water and a depth of the body of water.Type: ApplicationFiled: September 6, 2019Publication date: January 2, 2020Inventors: Jack A. Jones, Yi Chao, David M. Fratantoni, Michael Martin Zedelmair, Robin Edward Willis, Robert Scott Leland
-
Patent number: 10443581Abstract: A method of electricity production using water thermal energy includes compressing an enclosed working fluid at a first vertical position relative to a surface of a body of water to cause the fluid to move to a second vertical position relative to the surface and subsequently move to the first position in a closed loop, an external environment at the second position having a greater temperature than an external environment at the first position such that the fluid transitions between a liquid phase at the first position and a vapor phase at the second position, the compressing using power from a battery, and expanding the fluid at the second position to generate electricity to charge the battery. The first and second positions may be two depths of the body of water or a height of an atmosphere above the body of water and a depth of the body of water.Type: GrantFiled: October 31, 2017Date of Patent: October 15, 2019Assignee: Seatrec, Inc.Inventors: Jack A. Jones, Yi Chao, David M. Fratantoni, Michael Martin Zedelmair, Robin Edward Willis, Robert Scott Leland